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Background: Oral bovine colostrum prophylaxis accelerates the recovery of dextran sulfate sodium (DSS)-induced
colitis. In the present study the beneficial effects on acute intestinal inflammation of two major colostral
components, secretory immunoglobulin A and lactoferrin, were investigated. Outbred NMRI mice received whole
bovine colostrum (BC, 20 mg/kg body weight), colostral bovine lactoferrin (bLf, 150 mg/kg), or secretory
immunoglobulin A (sIgA, 1–2 mg/kg body weight) daily by oral gavage, either two weeks before induction of
colitis (prophylaxis) or after disease establishment (therapy). Bovine serum albumin (BSA, 150 mg/kg body weight)
and immunoglobulin G (IgG, 1 and 2 mg/kg body weight) served as protein controls. Colitis was induced by
providing 5% DSS solution ad libitum for seven days.
Results: Compared to BSA, BC therapy improved occult blood, stool consistency, and clinical recovery from colitis
but did not prevent initial weight loss. In contrast, administration of bLf did not influence the course of colitis in
either the prophylactic or the therapeutic setting. Therapeutic application of sIgA promoted weight gain in the
recovery phase of colitis but failed to improve other clinical parameters. Prophylactically-fed sIgA influenced
immune cell redistribution, normalized peripheral blood CD11c+CD83+ mature dendritic cells, modulated colonic
immune cell infiltration, and altered the numbers of both DSS-induced regulatory γδ TCR+ T cells and CD11b+Gr-1+
myeloid suppressor cells in the lymph nodes and spleens of mice.
Conclusions: These data demonstrated the potential of colostrum in disease recovery and epithelial homeostasis
following intestinal injury. Colostral sIgA failed to improve acute disease activity but promoted weight gain and
modulated immune cell responses that are involved in the genesis of colitis.
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Crohn’s disease and ulcerative colitis are chronic inflam-
matory disorders of the gut that cause major life-long dis-
ability. Afflicting mostly young people at an age when they
are most active both in their private and professional life,
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distribution, and reproduction in any mediumpublic health problem affecting the patients education,
working abilities, social life and quality of life. The cause
of IBD is multiple and so far not completely understood.
However, genetic factors, environmental factors and the
gut bacteria play a role in disease development.
Conventional therapy of active IBD pre-dominantly tar-
get anti-inflammatory immune responses, largely due to
cytokine release within the intestine. Thus, therapeutic
treatment mainly includes anti-inflammatory drugs,
immunosuppressants, biologic agents, and antibiotics [1].
However, these agents may cause severe adverse effects
and are therefore not suitable for long-term treatment of
IBD. Moreover, conventional drugs block manifestation or
consequences of inflammation in acute disease. Thus,tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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improvement of impaired barrier function in remission.
Suitable candidates are dietary supplements and food
components such as colostrum. Although natural therap-
ies are commonly associated with lower toxicity and fewer
side effects than conventional drugs, the scientific proof of
their effectiveness and safety is demanded [2].
Colostrum, the secretion produced by the mammary
glands during the first three days post-partum, contains
many functional nutrients. These include immunoglob-
ulins, growth factors, and antimicrobial peptides. The po-
tential of colostrum to affect gastrointestinal infections and
to reduce the incidence of immune-mediated diseases is
well established [3,4]. In accordance with this, we recently
demonstrated the protective effect of orally applied colos-
trum in a murine colitis model [5]. Beneficial effects were
characterized by improvement of clinical colorectal in-
flammation symptoms and by the induction of immu-
noregulatory mechanisms, predominantly of the innate
immune system arm. Thus, identification of factors re-
sponsible for preventing experimental colitis might provide
the basis for developing a long-term treatment regimen.
In IBD patients, local production of polymeric IgA
(pIgA) is altered and this affects both immunological
homeostasis and humoral immune responses [6,7]. IgA
does not activate the classical complement pathway and
inhibits the production of pro-inflammatory cytokines in
response to lipopolysaccharide (LPS), thereby maintaining
mucosal integrity [8]. SIgA preparations from colostrum
are active against various microbial antigens and inhibit
adhesion and invasion by enteropathogenic Escherichia
coli in vitro [9,10]. Colostral sIgA influences the develop-
ment of the gastrointestinal immune system in milk-fed
infants; however, little is known about the effectiveness of
oral sIgA in maintaining gut barrier functions in adults.
Another colostral peptide with a broad range of immu-
nomodulatory properties is lactoferrin (Lf), a member of
the iron-binding glycoprotein family. Lf is predominately
found in mucosal secretions and neutrophilic granules
[11]. Lf concentration and iron saturation differ among
species; bovine (bLf) and human (hLf) Lfs show strong
sequence homology [12]. BLf has been reported to stimu-
late mucosal and systemic immune responses when given
orally [13,14]. Moreover, there is experimental evidence
that Lf reduces the severity of colitis in rodents [15,16].
In the present study, we explored the potential of or-
ally applied colostral bLf and sIgA for modulating im-
mune responses and recovery from dextran sodium
sulfate (DSS)-induced murine colitis. Whole bovine col-
ostrum (BC) improved the clinical severity of colitis,
whereas bLf had no effect. SIgA influenced DSS-mediated
immune cell redistribution and specifically altered colonic
cell infiltration. Therefore, it might be an interesting can-
didate for promoting regeneration from acute colitis.Results
Therapeutic application of colostrum and sIgA improved
clinical recovery from colitis
After a single seven-day treatment of 5% DSS in drinking
water, the mice showed signs of acute colitis including
weight loss, bloody stools, and diarrhea. During the induc-
tion phase of colitis, neither the treatment (BC, sIgA, bLf)
nor the control (NaCl, IgG, BSA) groups differed signifi-
cantly with respect to body weight (Figure 1A). However,
disease activity in the acute phase of inflammation (day 4
to day 7) declined only after BC-feeding owing to reduced
occult blood (P = 0.008 vs. BSA, Figure 1C) and enhanced
stool consistency (P = 0.028 vs. BSA, Figure 1D).
During the recovery phase, mice receiving therapeutic
sIgA gained more weight than controls receiving NaCl
(P = 0.077) or BSA (P = 0.002). BC and bLf showed only
marginal differences from the control groups (NaCl, IgG,
BSA). Since BSA-fed mice showed the most dramatic
weight loss, up to 20% at day 14, the BC- and sIgA-
induced recovery was not simply attributable to a feeding
effect (Figure 1B).
Therapeutic application of colostrum or colostral
components had no effect on histopathological severity
of colitis
In contrast to the clinical benefit, BC and sIgA did not
reduce colon shortening at day 15 after DSS challenge.
In all experimental groups, colon lengths were signifi-
cantly lower than those in controls not treated with DSS
(see Additional file 1). Histological examination of the
colon at day 15 revealed no significant differences in
total histological score or in grade and extent of inflam-
mation (see Additional file 1).
Therapeutic application of sIgA affected immune cell
redistribution
The induction of colitis is characterized by a reduced
number of mature CD11c+CD83+ dendritic cells (DCs)
in the periphery and spleen and by a raised level in
the mesenteric lymph nodes. Therapeutic application of
Igs normalized the distribution of CD11c+CD83+ cells
compared to NaCl controls by increasing their numbers
in the spleens of sIgA-fed and in the peripheral blood of
IgG-fed mice. Inflammation-induced elevation of DCs in
mesenteric lymph nodes was exclusively found in NaCl
controls; their numbers were not altered in the thera-
peutic groups (Figure 2A). In addition to DCs, γδ TCR+
T cells are significantly influenced by DSS-induced col-
itis [5], and the levels of this cell population were higher
in the mesenteric lymph nodes and spleens of DSS-
exposed mice than in untreated controls. However, ex-
cept in the case of IgG, therapeutic application of BC or
Lf did not significantly alter the DSS-mediated cell redis-
tribution (Figure 2B). Taking these findings together, the
Figure 1 Influence of therapeutically applied colostral compounds on clinical severity of DSS-induced colitis. The indicated therapeutics
(bLf, sIgA, IgG, and BC) and controls (NaCl and BSA) were applied parallel to DSS treatment. Weight loss was either represented during the
induction phase of colitis as percentage of body weight from day 1 (A) or during the recovery phase as percentage from day 8 (B). Clinical
disease activity was determined by scoring changes in body weight, occult blood (C) and stool consistency (D) as shown in Additional file 3.
Values are means ± SD of n = 8 (NaCl), n = 6 (BC, sIgA, IgG), and n = 5 (bLf, BSA) mice.
Bodammer et al. BMC Immunology 2013, 14:10 Page 3 of 9
http://www.biomedcentral.com/1471-2172/14/10observed clinical benefit of sIgA treatment could partly
be explained by systemic immunological alterations.
Effect of prophylactically applied secretory IgA on clinical
severity of colitis
Next, we analyzed the potential of sIgA in a prophylactic
setting. IgG served as control and BC as positive control.
During the feeding period, sIgA and IgG were well
tolerated by all mice and no side effects such as lethargy,Figure 2 Leukocyte distribution in peripheral blood, lymph nodes an
therapeutics (bLf, sIgA, IgG, and BC) and controls (NaCl and BSA) were app
animals without any intervention. Values are presented as percent positive
as mean ± SD; n = 12 (Untreated) n = 8 (NaCl), n = 6 (BC, sIgA, IgG), and n =
U-test.abdominal pain or diarrhea were observed. Initial weight
loss from day 1 to day 7 remained unchanged in all ex-
perimental groups (Figure 3A). In the recovery phase,
weight gain was enhanced within the BC group until the
end of the experiments (Figure 3B), and BC ameliorated
clinical DAI (P = 0.025 vs. IgG) owing to improved stool
consistency (P = 0.045 vs. IgG) (Figure 3C and D). Clinical
recovery did not differ significantly between sIgA- and
IgG-fed mice (Figure 3B and C).d spleen at day 15 after starting DSS exposure. The indicated
lied parallel to DSS treatment. The untreated group represents healthy
CD11c+CD83+(A) or γδTCR+(B) of 10,000 measured events and given
5 (bLf, BSA). *p < 0.05 vs. Untreated; +p < 0.05 vs. NaCl, Mann Whitney
Figure 3 Influence of prophylactically applied immunoglobulins and whole BC on clinical severity of DSS-induced colitis. The indicated
therapeutics (sIgA, IgG, and BC) and control (NaCl) were applied parallel to DSS treatment. Negative control was represented from the therapeutic
setting (NaClTh). Weight loss was either shown during the induction phase of colitis as percentage of body weight from day 1 (A) or as weight
loss during the recovery phase as percentage body weight from day 8 (B). Clinical disease activity (DAI) (C) was determined by scoring changes
in body weight, occult blood and stool consistency (D) as described in the Methods section. Values are mean ± SD of n = 8 (NaClTh), n = 6 (BC),
n = 6-8 (sIgA), and n = 5-8 (IgG) mice.
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improve histopathological changes of colitis but affected
colonic cell infiltration
Colon length (data not shown) and total median histo-
logical score did not differ significantly among any of
the DSS-exposed experimental and untreated control
groups (see Additional file 2). Therefore, a detailed immu-
nohistochemical analysis from colonic sections was per-
formed to unravel the observed clinical benefit (Figure 4A).
The numbers of CD4+ and γδ TCR+ T cells and of CD11c+
and CD83+ mature dendritic cells were markedly higher in
the BC and sIgA groups than in IgG-fed mice (Figure 4B).
These data argued for a specific local immune modulation
by BC and colostral sIgA.
Prophylactically applied secretory IgA normalized DSS-
mediated redistribution of immune cells
We next examined whether immunological effector cells
were influenced by sIgA in other lymphatic organs. Prophy-
lactic application of sIgA normalized T cell numbers in
spleen and mesenteric lymph nodes. Levels of CD3+CD4+
cells were similar to those in the untreated control mice.
Interestingly, neither IgG nor BC affected T cell numbers,
indicating a specific sIgA-mediated response (Figure 5A).
Comparable though less pronounced effects were ob-
served for splenic γδ TCR+ cells (Figure 5B). In mesen-
teric lymph nodes, a similar modulation of immune cell
distribution was found. Here again, levels of mature
CD11c+CD83+ dendritic cells were specifically normalizedby sIgA prophylaxis (Figure 5C). Taken together, these
data clearly pointed to immunological alterations by sIgA
prophylaxis that influenced colonic inflammation.
Prophylactically applied secretory IgA increased levels of
DSS-induced myeloid-derived suppressor cells
Myeloid-derived suppressor cells (MDSC) represent an-
other cell population that is altered during the course of
colitis [5]. The MDSC population is heterogeneous and
is characterized by CD11b+ and Gr1+ co-expression.
These cells are induced by DSS exposure and accelerate
recovery from colitis following transplantation [17]. Ac-
cordingly, the total levels of splenic CD11b+Gr1+ cells
were higher in DSS-exposed mice than in healthy un-
treated controls on day 15 (Figure 6). While BC prophy-
laxis nearly normalized splenic CD11b+Gr1+ cell
numbers, sIgA did not. In sIgA-fed mice, the numbers
of MDSCs were massively increased (Figure 6A). It is
notable that these effects were evident in all three
subpopulations (CD11b+Gr1+low, int, high); MDSC levels
were more than three-fold higher than in IgG and BC-
exposed mice (Figure 6B).
Discussion
As shown in a previous study, oral BC prophylaxis
accelerates recovery from DSS-induced colitis [5]. How-
ever, most treatment regimens for IBD patients are not
available before the onset of disease. Therefore, the
present study was undertaken to evaluate the potential
Figure 4 Colonic infiltration of prophylactically-fed, DSS-exposed mice and untreated control without intervention at day 15.
The indicated therapeutics (sIgA, IgG, and BC) were applied parallel to DSS treatment. The untreated group represents healthy animals without
any intervention. A: Immunohistochemical staining of a) CD11c+ mature dendritic cells or b) γδTCR+ T-cells in the colon of DSS-exposed mice
compared to untreated, healthy controls. Representative images are shown in 200-fold magnification. B: Impact of prophylactic sIgA on cell
distribution in lymph nodes and spleen at day 15. The indicated therapeutics (sIgA, IgG, and BC) were applied parallel to DSS treatment. The
untreated group represents healthy animals without any intervention. Values are given as percent CD3+CD4+(A), γδTCR+(B), or CD11c+CD83+(C)
positive cells of 10,000 measured events and given as mean ± SD. n = 6-8 (Untreated), n = 6 (BC, sIgA), and n = 5 (IgG) mice. *P < 0.05 vs.
untreated, Mann Whitney U-test.Values are means ± SD of n = 6 (Untreated, BC, IgA) and n = 5 (IgG) mice.* P < 0.01 vs. untreated, +P < 0.05 vs. IgG,
Mann Whitney U-test.
Figure 5 Impact of prophylactic sIgA on cell distribution in lymph nodes and spleen at day 15. The indicated therapeutics (sIgA, IgG, and
BC) were applied parallel to DSS treatment. The untreated group represents healthy animals without any intervention. Values are given as percent
CD3+CD4+ (A), γδTCR+ (B), or CD11c+CD83+ (C) positive cells of 10,000 measured events and given as mean ± SD. n=6-8 (Untreated),
n=6 (BC, sIgA), and n=5 (IgG) mice. *P<0.05 vs. untreated, Mann Whitney U-test.
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Figure 6 Impact of prophylactic sIgA on DSS-induced myeloid-derived suppressor cells at day 15. The indicated therapeutics (sIgA, IgG,
and BC) were applied parallel to DSS treatment. The untreated group represents healthy animals without any intervention. Values are provided as
percent total CD11b+Gr-1+ cells positive cells (A) or subpopulations with low, intermediate (int) or high CD11b+Gr-1+ co-expression in 10,000
measured events (B). Values are given as mean ± SD. n = 6-8 (Untreated), n = 6 (BC, sIgA), and n = 5 (IgG) mice. *P < 0.05 vs. untreated, +P < 0.05
vs. sIgA, n.s. = not significant IgG vs. sIgA, Mann Whitney U-test.
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sIgA and bLf in a therapeutic setting. Both compounds
display immunomodulatory potential [6,11], are resistant
against proteolytic degradation, and accumulate in blood
and intestinal tissue of mice [18,19].
The major finding of the study was that whole BC and
in part colostral sIgA improved clinical recovery from
colitis when applied therapeutically. This conclusion was
confirmed by the enhanced weight gain of sIgA-fed mice
and the lower disease activity (occult blood, diarrhea) in
the BC-fed treatment group. Although BC and sIgA
prevented neither the initial weight loss after induction
of colitis nor the histological outcome of colitis, sIgA-
and BC-fed mice recovered more quickly than control
animals. In striking contrast, bLf failed to improve the
clinical and histological course of colitis after both thera-
peutic and prophylactic applications (data not shown).
This was surprising since bLf showed anti-inflammatory
potential in DSS-induced colitis and stimulated mucosal
and systemic immune responses when given orally [13,14].
In addition, reduced LPS-induced epithelial damage and
barrier destruction have been reported [20], as well as
decreased rectal bleeding and an improved histological
score [15]. These findings, seemingly contradictory to our
study, could be attributed to the fact that in these studies,
human Lf with 7% iron saturation level was applied
perorally twice a day. In contrast, we used Lf derived from
bovine colostrum, and the level of iron saturation of bo-
vine Lf was in range of 5 to 30%. Therefore, the discrep-
ancy might be due to the therapeutic regimen rather thanto the iron saturation level. Thus, increasing the number
of Lf injections per day might have beneficial effects on
the course of colitis. However, this was beyond the scope
of the present study.
Another remarkable finding of our study was the effect
of immunoglobulins on those immunological effector
cells that most probably promote disease recovery. Ma-
ture DCs (CD11c+CD83+) and immunoregulatory γδ
TCR+ T cells were almost normalized in lymph nodes
and spleens in the sIgA and IgG groups. Similar data
were obtained in the prophylactic setting. SIgA almost
normalized the DSS-mediated cell redistribution (CD4+ T
helper cells, γδ TCR+ T cells, CD11c+CD83+ mature den-
dritic cells) in lymph nodes and spleen.
Although γδ T cells are important in intestinal inflam-
mation, the functional role of this cell population remains
unknown. Under physiological conditions, they represent
a minor subset within lymph nodes and spleens; however,
they are induced in mice and men by inflammatory
responses [21,22]. Peripheral human γδ T cells exert regu-
latory functions and suppress T helper cell proliferation
[23]. Thus, the specific effects of sIgA on immune cell dis-
tribution can be regarded as favorable immune modula-
tion of DSS-induced inflammation. In addition, colostral
sIgA but not IgG influenced colonic cell infiltration. Just
as whole BC is effective in preventing DSS-induced colitis,
so sIgA treatment was characterized by massive increases
in colonic CD11c+ and CD83+ DCs as well as γδ TCR+ T
cells. Thus, the increase of local regulatory cells after BC
prophylaxis was most likely to have been due to colostral
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to promote epithelial cell growth via the production of kera-
tinocyte growth factor [24] and to regulate intestinal
homeostasis [25], while depletion of γδ T cells worsened in-
flammation in mouse models of colitis [26,27]. Therefore, in
accordance with these studies, the enhanced recovery from
colitis was most probably mediated by immune cell modula-
tion through colostrum and in particular colostral sIgA.
In our previous study, we hypothesized that MDSCs
contributed to the clinical benefit of prophylactically ap-
plied colostrum [5]. Here again, sIgA prophylaxis specifi-
cally increased the number of splenic CD11b+Gr-1+ MDSCs.
Although the function of CD11b+Gr-1+ MDSC in intestinal
inflammation remains unclear, MDSCs accumulated in the
bone marrow and spleen of DSS-exposed mice, and intraven-
ous transplantation of DSS-induced splenic CD11b+Gr-1+
cells in C57Bl/6 mice resulted in advanced mucosal healing
[17]. We therefore conclude that the strong induction of
CD11b+Gr-1+ cells by sIgA contributed to the enhanced re-
covery from weight loss at later time points.
Conclusions
In conclusion, we tested the immunomodulatory potential
of sIgA and bLf for improving the severity of DSS-induced
murine colitis. SIgA but not bLf was identified as a
colostral component that altered immune responses and
promoted weight gain in colitic mice. Further studies are
required to explore how this natural colostral compound
modulates the colitis-induced immune cell redistribution.
Methods
Mice
Female outbred NMRI mice were purchased from Harlan
Winkelmann GmbH (Melderslo, Netherlands) at the age of
four to six months. They received standard food and water ad
libitum. Mice aged eight to twelve months (average body
weight 30 g) were randomly assigned to different experimental
groups. All animal experiments were performed in compli-
ance with the German animal protection law (TierSchG BGBI
S. 1105; 25.05.1998) and were approved by the local commitee
on the ethics of animal experiments of the University of Ros-
tock (Landesamt für Landwirtschaft, Lebensmittelsicherheit
und Fischerei Mecklenburg-Vorpommern) under permit
number 2007/06/14;LALLFM-V/TSD/7221.3-1.1-059/08.
Colostrum, lactoferrin and secretory immunoglobulin a
For the therapeutic setting, BC powder (SANIMALIS,
Heinsberg, Germany) was skimmed, pasteurized, and
freeze-dried to ensure minimum denaturation of immu-
noglobulins and nutrients. The total protein content of
the colostrum preparation was 60–70 g/100 g.
The BC (SANIMALIS) solution used for prophylactic
treatment was skimmed, casein-free and sterile-filtered.
The concentrations of immunoglobulin and other majoringredients were as previously described [5]. The total pro-
tein content was 7.25 g/100 ml (carbohydrate 0.2 g/100 ml,
fat < 0.01 g/100 ml).
BLf was purified from bovine, and sIgA from human
colostrum. IgG was isolated from human serum. All
therapeutic agents were purchased from Sigma-Aldrich
(Taufkirchen, Germany). Bovine BSA (Sigma-Aldrich)
served as control.
Induction of colitis
Acute colitis was induced by DSS, as previously described
[28]. Briefly, DSS (36–50 kDa; MP Biomedicals, Eschwege,
Germany) was dissolved in sterilized tap water and pre-
sented to the mice at a final concentration of 5% for seven
days. Fresh DSS solution was provided every second day.
Therapeutic treatment protocol
All therapeutic interventions were initiated from day 3
after starting DSS exposure until the end of the experiment
(day 15). Either 20 mg/kg bw BC powder (BC, n = 6),
1 mg/kg bw sIgA (sIgA, n = 6), IgG (IgG, n = 6), 150 mg/kg
bw bLf (bLf, n = 5) or protein control (BSA, n = 5) were
dissolved in physiological sodium chloride solution (0.9%
NaCl) and given to each mouse in a final volume of 100 μl
daily by oral gavage. DSS-treated negative controls re-
ceived 100 μl NaCl (DSS, n = 8). Physiological values
were obtained from animals with no intervention (un-
treated, n = 6-8).
Prophylactic treatment protocol
One hundred μl of pure BC (n = 6) was given to the
mice orally by gavage daily for 14 days. All prophylactic
treatments were initiated two weeks prior to colitis in-
duction. SIgA and IgG were dissolved in NaCl. Each
mouse received 2 mg/kg bw sIgA (n = 8) or IgG (n = 8) in
final volume of 100 μl daily for 14 days by oral gavage.
Clinical evaluation of colitis
After starting DSS exposure at day 1, the mice were
weighed daily until the end of the experiment at day 15.
Weight loss during the induction phase of colitis was
observed from day 1 to day 7 (day 1 = 100%), whereas
the recovery phase was defined as weight gain after stop-
ping DSS until the end of the experiment from day 8 to
day 14 (day 8 = 100%). Stool consistency was checked for
diarrhea and feces were screened for blood during the
acute inflammation phase of colitis from day 1 to day 7
(therapeutic protocol) or from day 1 to day 14 (prophy-
lactic protocol) using a HemoCARE occult blood detec-
tion kit (Care Diagnostica, Voerde, Germany). DAI was
determined according to Cooper et al. (1993) with minor
modifications, by scoring changes in fecal blood, and
stool consistency, as shown in Additional file 3 [29].
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Mice were killed on day 15 after starting DSS. At au-
topsy, whole colons were removed and their lengths
were measured. The colons were unrolled and divided lon-
gitudinally into two parts. One part was fixed and embed-
ded in paraffin. Sections were stained with hematoxylin and
eosin. The degree of colonic inflammation was analyzed by
a pathologist in a blinded fashion, according to the scoring
system originally described by Cooper et al. (1993) as
shown in Additional file 4 [29].
Flow cytometry
Flow cytometry was performed on leukocytes from pe-
ripheral blood, spleens, and mesenteric lymph nodes as
described previously [5]. Briefly, leukocytes were labeled
using the following fluorescein isothiocyanate (FITC)- and
phycoerythrin (PE)-conjugated anti-mouse monoclonal
antibodies (mAbs) at the appropriate concentrations:
CD3ε FITC, CD19 FITC, γδ TCR PE (ImmunoTools,
Fiesoythe, Germany), CD11b FITC, CD11c FITC, CD4
PE, CD8 PE; Gr-1 PE (Miltenyi Biotech, Bergisch-
Gladbach, Germany), CD83 PE (eBioscience, Frankfurt,
Germany). Negative controls consisted of lymphocytes
stained with the appropriate isotype controls. Myeloid-
derived suppressor cells (MDSC) were defined as CD11b+
Gr-1+. Subsets of these cell populations were detected by
gating on the CD11b+Gr-1+high, CD11b+Gr-1+intermediate,
or CD11b+Gr-1+low fraction, definable by varying expres-
sion intensity. Samples were analyzed on a FACSCalibur
Cytometer (BD Pharmingen) using CellQuest software
and gating on total leukocytes (BD Biosciences, Mountain
View, CA USA). Relative numbers are given.
Statistics
Values are reported as the mean ± standard deviation (SD).
To ensure reproducibility, experiments were repeated
twice with three to four mice per group (except therapeutic
experiment group DSS + bLf and DSS + BSA). Data from
separate experiments were combined for statistical analysis
and presentation in figures and tables. Owing to small
sample sizes, group and time effects of clinical parameters
(weight loss, DAI) were analyzed by a nonparametric one-
way ANOVA model for repeated measurements using SAS
9.2 software [30]. To analyze the impact of DSS-colitis on
histological parameters (cell infiltration and distribution,
colon length) we first compared between untreated and
NaCl groups. To analyze the influence of the treatment
during the course of colitis, comparison was made between
NaCl and the susceptive treatment group (BC, sIgA, and
bLf). For the impact of BC and sIgA, we used BSA as ap-
propriate protein control. To analyze whether observed
immunoglobulin-induced effects are specific for sIgA, we
used IgG as control. Analyses were performed with the
parameter-free Mann Whitney U-test using SPSS software[31]. P < 0.05 was considered the criterion for statistical
significance.
Additional files
Additional file 1: Figure S1. Influence of therapeutics on colon length
(A) and histological score (B) of DSS-induced colitis. Figure S1 shows the
influence of therapeutically applied BC, sIgA, bLf, control protein IgG, and
BSA on histological severity of DSS-induced colitis. Colon length (A) and
histological score (B) were analyzed at day 15 after starting DSS-exposure
as indicated in the methods section. Values are means ± SD (A) or
medians as horizontal line (B), of n = 12 (Untreated), n = 8 (NaCl), n = 6
(IgG), n = 5 (sIgA, BC, bLf), and n = 4-5 (BSA) mice. * P < 0.01 vs. Untreated
Mann Whitney U-test.
Additional file 2: Figure S2. Influence of prophylactic-applied
therapeutics on histological severity of DSS-induced colitis. Figure S2
shows the histological severity of DSS-induced colitis following
prophylactic application of BC, sIgA, and control protein IgG. Values are
shown as medians (horizontal line) of n = 6 (sIgA, BC), and n = 5
(IgG) mice.
Additional file 3: Table S1. Disease activity index after DSS-exposure.
Table S1 shows the scoring of the disease activity index after DSS
exposure modified according to Cooper HS, Murthy SN, Shah RS,
Sedergran DJ: Clinicopathologic study of dextran sulfate sodium
experimental murine colitis. Lab Invest 1993; 69:238–249. The disease
activity index is determined by summing the scores for weight loss,
occult blood/gross bleeding, and stool consistency (maximal score = 10).
Slightly positive stool was defined as incomplete colored occult blood
test. Positive occult blood test was defined as complete, intensive
colored occult blood test. Gross bleeding was defined as fresh, visible
blood on the fur around the anus. Normal stool is defined as well-formed,
compact pellets, loose stool is defined as a pasty but formed stool, and
diarrhea is defined as liquid stool.
Additional file 4: Table S2. Histological scoring of DSS-exposed mouse
colons. Table S2 shows the histological scoring of DSS-exposed mouse
colons. Modified according to Cooper HS, Murthy SN, Shah RS, Sedergran
DJ: Clinicopathologic study of dextran sulfate sodium experimental
murine colitis. Lab Invest 1993, 69:238–249. Tissue sections were scored
separately for the amount and extent of inflammation, the amount of
crypt damage, or regeneration and the percentage of involved tissue.
The total histological score was generated by adding the product of the
grade and the involvement of each feature to a maximum value of 40.
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